Organogenesis Holdings Inc. (ORGO): Results of Operations and Financial Condition
Organogenesis Holdings Inc. (ORGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 orgo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results CANTON, Mass., (August 6, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovat
How this was made
The 30-second read
Why it matters
The newest disclosed facts are the magnitude of revenue contraction and the worsening loss profile (net loss, adjusted net loss, and adjusted EBITDA loss), plus margin deterioration and higher R&D spend. These are likely to drive immediate repricing of forward expectations and risk appetite for the name.
Market read
Q2 2026 results show a steep YoY revenue decline and substantially larger losses, with gross margin dropping sharply, making this a high-signal earnings-style update for ORGO.
What to watch
Gross margin fell to 45% from 73% of revenue, while R&D increased 76% YoY; traders should separate near-term profitability pressure from longer-cycle product and ReNu program investment.
Background
The 8-K (Item 2.02) reports Organogenesis’ second quarter 2026 financial results ended June 30, 2026, including segment revenue, gross profit, operating expenses, and loss metrics.
Ticker impact
Organogenesis reported Q2 2026 net revenue of $42.8M, down 58% YoY, with net loss of $96.3M and widening adjusted EBITDA loss.
Near-term downside bias and elevated volatility versus prior expectations, as the magnitude of revenue and loss deterioration is the dominant new datapoint.
This is a primary-source 8-K with detailed quarterly financial results, including revenue by segment and loss metrics that clearly worsen year over year.
Market effects
Regenerative medicine and advanced wound care names may face renewed scrutiny on demand durability and margin compression when ORGO shows large revenue declines.
Limited direct regional spillover; impact is primarily company-specific within US small/mid-cap healthcare.
Low global relevance; the disclosure is specific to ORGO’s product lines and financial condition.
Counterpoint
Management cites “measured improvement” in business trends and expanding share as the market resets, which could mean the revenue decline is partly timing-related rather than structural collapse.
Key entities
- companyOrganogenesis Holdings Inc.
Nasdaq-listed regenerative medicine company reporting Q2 2026 results on Form 8-K.
- executiveGary S. Gillheeney
CEO and Chair, quoted on measured improvement but slower-than-expected recovery.
